February 2026
Ayahuasca
What February 2026's 7 new studies found, synthesized from the papers below. All Ayahuasca research →
The synthesis
Synthesized from 7 studies in the library · AI-generated, grounded in the abstracts below
Found by searching the library for Ayahuasca, yage, hoasca, banisteriopsis, then ranked by relevance.
Research on ayahuasca in February 2026 indicates promising therapeutic potential for mental disorders, particularly in enhancing neuroplasticity and reducing stress-induced cortical atrophy, but the evidence remains largely preclinical or observational. A key caveat is the need for randomized controlled trials to confirm efficacy and safety, especially given identified risks of drug-drug interactions with SSRIs and contraindications for psychotic or bipolar individuals.
Evidence by study
Direction is which way each study's own result points, not our rating of the study.
What the directions mean
- Supports:
- the study found the intervention worked, or its hypothesis held.
- Opposes:
- it found the opposite, no benefit or a harm.
- No effect:
- no significant difference either way.
- Mixed:
- effects in both directions within the same study.
- Unclear:
- the abstract does not report a direction.
| Study | Design | Sample size | Direction | Finding |
|---|---|---|---|---|
| Ayahuasca and Its Main Component N,N-Dimethyltryptamine (DMT) for the Treatment of Mental Disorders: Mechanisms of Action, Clinical Studies, and Tools to Explore the Human Mind 2026 | review | Supports | This review concludes that current evidence offers an optimistic outlook on DMT and 5-MeO-DMT efficacy for treatment-resistant psychiatric disorders, though clinical trials are limited. | |
| Ayahuasca, DMT, and Mental Health: A Current Review of Scientific Studies 2026 | review | Supports | This review summarizes that ayahuasca shows promise for depression, anxiety, PTSD, and substance use disorders, but evidence is mainly observational and requires randomized trials. | |
| Preliminary analysis of ayahuasca-induced anatomical alterations in the somatosensory cortex of juvenile non-human primates (Callithrix jacchus) subjected to chronic stress 2026 | preclinical | Supports | Ayahuasca treatment before and during chronic stress prevented neuronal volume reduction in the somatosensory cortex, suggesting a prophylactic effect against stress-induced cortical atrophy. | |
| Predicting drug–drug interactions between ayahuasca alkaloids and SSRIs using physiologically based pharmacokinetic modeling 2026 | modeling study | Opposes | Physiologically based pharmacokinetic modeling predicts a clinically relevant interaction between ayahuasca and SSRIs, potentially increasing serotonergic effects and risk. | |
| RESENHA CRÍTICA DA OBRA VISÕES MULTIDISCIPLINARES DA AYAHUASCA 2026 | review | Supports | This critical review of a multidisciplinary book highlights ayahuasca's therapeutic potential in mental health and its mechanisms of action, but notes the anthropological analysis could have explored traditional knowledge more deeply. | |
| Representing mental images and immaterial processes in VR. A new materialist reading of Manic VR and Ayahuasca – Kosmik Journey 2026 | theoretical | Unclear | This theoretical article analyzes how VR represents mystical-type experiences associated with psychedelic use, but does not provide empirical evidence on ayahuasca's effects. | |
| Ayahuasca modulation of traumatic-like fear memories requires infralimbic cortex BDNF-dependent mechanisms in rats. 2026 | preclinical | Supports | Repeated ayahuasca administration enhanced fear extinction learning and retention, and reduced fear generalization, effects dependent on BDNF-TrkB signaling in the infralimbic cortex. |
This review concludes that current evidence offers an optimistic outlook on DMT and 5-MeO-DMT efficacy for treatment-resistant psychiatric disorders, though clinical trials are limited.
review
This review summarizes that ayahuasca shows promise for depression, anxiety, PTSD, and substance use disorders, but evidence is mainly observational and requires randomized trials.
review
Ayahuasca treatment before and during chronic stress prevented neuronal volume reduction in the somatosensory cortex, suggesting a prophylactic effect against stress-induced cortical atrophy.
preclinical
Physiologically based pharmacokinetic modeling predicts a clinically relevant interaction between ayahuasca and SSRIs, potentially increasing serotonergic effects and risk.
modeling study
This critical review of a multidisciplinary book highlights ayahuasca's therapeutic potential in mental health and its mechanisms of action, but notes the anthropological analysis could have explored traditional knowledge more deeply.
review
This theoretical article analyzes how VR represents mystical-type experiences associated with psychedelic use, but does not provide empirical evidence on ayahuasca's effects.
theoretical
Repeated ayahuasca administration enhanced fear extinction learning and retention, and reduced fear generalization, effects dependent on BDNF-TrkB signaling in the infralimbic cortex.
preclinical
Points of agreement
- Ayahuasca and DMT show potential for treating mental disorders, particularly through enhancing neuroplasticity and modulating brain networks.
- Preclinical studies indicate ayahuasca can reduce stress-induced neural atrophy and improve fear extinction.
- The evidence is predominantly from preclinical and observational studies, with a consensus that randomized controlled trials are needed.
Conflicts
- No direct conflicts among the studies; however, the positive preclinical findings contrast with the caution raised by the drug-drug interaction modeling study.
Gaps
- No new clinical trials in humans were reported in the provided abstracts.
- Durability of therapeutic effects and long-term safety are not addressed.
- Studies lack diverse populations, including female subjects and adolescents.
- The interaction between ayahuasca and SSRIs requires controlled clinical investigation.